Lipika Goyal

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Clinical benefit of various HER2-directed regimens in gastrointestinal malignancies: a retrospective cohort study

  BMC Cancer · 2026-06-10

• Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models

  Science Translational Medicine · 2026-06-03

• Activating a B cell immune response regresses immunologically cold tumours

  Nature Nanotechnology · 2026-06-01 · 1 citations

• ARTEMIDE-Biliary02: A phase 3, randomized, global study of rilvegostomig or durvalumab with chemotherapy as first-line (1L) treatment for advanced biliary tract cancer (BTC).

  Journal of Clinical Oncology · 2026-05-28

• Harnessing Artificial Intelligence for the Management of Patients With GI Cancers

  American Society of Clinical Oncology Educational Book · 2026-04-27

• An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis

  Liver Cancer · 2026-04-24 · 1 citations

• Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses

  Hepatology · 2026-02-02

• Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).

  Journal of Clinical Oncology · 2026-01-10 · 2 citations

• ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).

  Journal of Clinical Oncology · 2026-01-10

• Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.

  Journal of Clinical Oncology · 2026-01-10 · 5 citations

• Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials

  Cancer · 2025-12-19 · 1 citations

• Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11

• Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

  2025-12-11